TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male 18-50 yrs old~* In good general health based on normal screening evaluation (consisting of medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)~Exclusion Criteria:~* Poor general health, with abnormal blood results at screening~* A known history of alcohol or drug abuse~* Participation in a long-term male contraceptive study within three months of screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, \& 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All the patients diagnosed as having cirrhosis of liver~Exclusion Criteria:~* Overt HE or a history of overt HE;~* History of recent (\< 6 weeks) alcohol intake;~* Infection, recent (\< 6 weeks) antibiotic use or gastrointestinal bleeding;~* History of recent (\< 6 weeks) use of drugs affecting psychometric~* Performances like benzodiazepens, antiepileptics, psychotropic drugs;~* History of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension;~* Electrolyte imbalance;~* Renal impairment;~* Presence of hepatocellular carcinoma;~* Severe medical problems such as congestive heart failure, pulmonary disease, neurological or psychiatric disorder, etc., that could influence quality-of-life measurement;~* Inability to perform NP tests and to complete the SIP questionnaire due to bad vision.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of stage IV NSCLC.~* Have progressed during or after platinum-based chemotherapy for advanced disease.~* Have not received prior treatment with docetaxel.~* Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived material.~* Have adequate organ function including hematology, renal, and liver.~* Have good performance score (0-1).~* Have measurable disease per RECIST 1.1.~* Agree to use a reliable medically approved method of birth control.~Exclusion Criteria:~* Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment administered is not known.~* Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.~* Have the presence of unstable central nervous system (CNS) metastasis.~* Have had major surgery (excluding biopsy) \< 28 days of the initial dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib (Type: EXPERIMENTAL): 200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- Docetaxel (Type: ACTIVE_COMPARATOR): 75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 18-60 of all races and ethnicity.~2. Meets DSM-IV-TR criteria for a primary diagnosis of inattentive or combined type ADHD as diagnosed via the Adult ADHD Clinician Diagnostic Scale~3. For the Sluggish Cognitive Tempo+ group Must Score ≥ 5 items on the Barkley Sluggish Cognitive Tempo Scale; Must be rated 3 (often) or (very often) and total Sluggish Cognitive Tempo symptom score ≥ 26; must have a T-score ≥ 65 on the Metacognition Index and Motivation Subscales of the Behavior RatingInventory of Executive Function - Adult Version (BRIEF-A)~4. Impairment: must have a total score \> 95th percentile on the Barkley Functional Impairment Rating Screen (Barkley Functional Impairment Scale (BFIS).~5. For the Sluggish Cognitive Tempo - group, \< 5 items on the Barkley SCT Scale must be rated 3 (often) or 4 (very often) and total SCT symptom score \< 26; must have a T-score \< 65 on the Metacognition Index and Motivation Subscales of the BRIEF-A.~Exclusion Criteria:~1. Meets DSM-IV-TR criteria for a primary diagnosis of hyperactive-impulsive type ADHD.~2. Any other current psychiatric disorder, determined via the M.I.N.I , which requires pharmacotherapy treatment.~3. Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide Severity Rating Scale(C-SSRS).~4. Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I~5. Pregnant, breastfeeding or women planning to become pregnant.~6. Positive urine drug toxicology are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine First (Type: EXPERIMENTAL): In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
- Lisdexamfetamine Second (Type: EXPERIMENTAL): In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with nHCM (hypertrophied and non-dilated left ventricle in absence of systemic or other known cause), with LV wall thickness ≥ 15mm at Screening or ≥ 13mm with a positive family history of HCM.~* Age 18 and greater, Body weight \> 45kg~* Documented LVEF ≥ 55% at the Screening as determined by echo central lab~* LVOT gradient \< 30 mmHg at rest AND during Valsalva AND post-exercise~* NYHA functional class II or III~* Elevated NT-proBNP at rest~Key Exclusion Criteria:~* History of syncope, sustained ventricular tachyarrhythmia with exercise, obstructive coronary artery disease or myocardial infarction within the past 6 months~* History of resuscitated sudden cardiac arrest at any time or known appropriate implantable cardioverter defibrillator (ICD) discharge within 6 months prior to Screening~* Current treatment with disopyramide or ranolazine (within 14 days prior to Screening)~* Current or planned treatment during the study with a combination of beta-blockers and calcium channel blockers~* Has been treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\]) within 6 months prior to Screening~* History of resting or post-exercise LVOT \>30 mmHg unless subsequently treated by septal reduction~* Has QTc Fridericia (QTcF) \>480 ms or any other ECG abnormality considered by the investigator to pose a risk to participant safety (eg, second-degree atrioventricular block type II)~* Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate-controlled within 1 year of Screening~* History of clinically significant malignant disease within 10 years such as non-metastatic cutaneous squamous cell or basal cell carcinoma~* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or MyoKardia physician, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Active Treatment for participants with base target trough concentration
- Group 2 (Type: EXPERIMENTAL): Active Treatment for participants with higher target trough concentration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Human Leptin Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Congenital leptin deficiency (these are only 3 adult individuals in the world that have been identified as leptin-naïve thus far).~Exclusion Criteria:~* Pregnant, trying to become pregnant, breast-feeding an infant or sexually active women, not using contraception.~* Subjects with hemoglobin levels below 12 g/dl.~* Subjects whose body contains a ferromagnetic implanted device that might produce a safety hazard during fMRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant methionyl human leptin (Type: EXPERIMENTAL): Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib for Imatinib/Sunitinib-failed GIST

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years~* advanced GIST~* failed (progressed and/or intolerable) after prior treatments for GIST~* ECOG performance status of 0\~2~* resolution of all toxic effects of prior treatments~* no prior radiotherapy within 1 month before registration~* measurable lesion as defined by RECIST~* adequate marrow, hepatic, renal and cardiac functions~* provision of a signed written informed consent~Exclusion Criteria:~* severe co-morbid illness and/or active infections~* pregnant or lactating women~* history of other malignancies~* active CNS disease not controllable with radiotherapy or corticosteroids~* active and uncontrollable bleeding from gastrointestinal tract~* prior history of sorafenib use~* gastrointestinal obstruction or malabsorption syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): The patients will receive daily oral administration of sorafenib 400 mg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H. pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H. pylori-eradication therapy~* ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 7-day quadruple therapy (Type: EXPERIMENTAL): 1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days,~4. metronidazole 500 mg twice daily for 7 days
- 10-day sequential therapy (Type: EXPERIMENTAL): 1. pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~2. pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days.
- 7-day standard triple therapy (Type: ACTIVE_COMPARATOR): 1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of systemic lupus erythematosis (SLE) by the American College of Rheumatology (ACR) Criteria.~History of a positive antinuclear antibody (ANA) test result at any time in the past.~40 participants with history of mild to moderate SLE disease Minimally active or inactive SLE disease, i.e., (Safety of Estrogens in Lupus Erythematosis National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), SELENA-SLEDAI ≤2 at the start of the study.~Age ≥ 18 years and ≤ 50 years. Gender: females Ability to provide informed consent. Maintenance Prednisone dose ≤ 15 mg/day. Plaquenil ≤ 400 mg/day.~Exclusion Criteria:~Hypersensitivity to any vaccine component Active infections including but not limited to human immunodeficiency virus (HIV positive), Hepatitis B or C, tuberculosis.~Positive purified protein derivative (PPD) test results without evidence of prior treatment or administration of bacilli Calmette-Guerin (BCG) vaccine. A positive PPD is defined as ≥ 5 mm induration 24-38 hours after receiving 5TU (TU=tuberculin units) of PPD.~Pregnancy or desire to become pregnant during the study period. Breast feeding. Inability to complete the immunization series. Received any blood product or component in the previous 6 months before enrollment.~Received any inactivated vaccine product within 14 days before enrollment. Received any live vaccine product within 21 days before enrollment.~Fever (temperature \> 100°F) at the time of enrollment. Inability to provided informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Gardasil (Type: EXPERIMENTAL): 0.5 ml single dose Gardasil vaccine given at three separate visits

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Therapy Using Lenalidomide in Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No signs of progression after transplant~* Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males)~* No active severe infection~* Satisfactory restoration of the haematological parameters defined by: PN \>1,000/mm3 and Platelets \> 75,000/mm3~* Bilirubin \< 35 umol/l and GOT/GPT/PAL\<3N~* Creatinine \< 160 umol/l.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- placebo group (Type: PLACEBO_COMPARATOR): Administration of oral placebo
- lenalidomide group (Type: EXPERIMENTAL): Administration of lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* over 8 weeks s/p scar~* linear closure~* visibly symmetric scar~* over 18 years old~Exclusion Criteria:~* concomitant treatment of involved skin~* propensity for keloid scarring~* use of oral retinoids for the past 1 year~* pregnancy~* immunosuppression~* prior laser to the area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age at time of screening.~* Screening laboratory result indicating hepatitis C virus (HCV) genotype 1 (GT1) infection.~* Chronic HCV infection.~* Subject must be HCV treatment-naïve (i.e., patient has never received a single dose of any approved or investigational regimen) or treatment-experienced (has failed prior interferon \[IFN\] or pegylated IFN (pegIFN) with or without ribivarin (RBV), or sofosbuvir (SOF) plus RBV with or without pegIFN therapy).~* Subjects must be non-cirrhotic.~Additional Inclusion Criteria for HCV GT1/human immununovirus type 1 (HIV-1) co-infected patients:~* HIV-1 antiretroviral treatment (ART) naïve with CD4 ≥ 500 cells/mm3 (or CD4+ % ≥ 29%) at Screening and plasma HIV-1 RNA \<1,000 copies/mL at Screening and at least once during the 12 months prior to Screening.~OR~* On a stable, qualifying HIV-1 ART regimen for at least 8 weeks prior to screening, with CD4 ≥ 200 cells/mm3 (or CD4+ % ≥14%) at Screening and plasma HIV-1 RNA \< LLOQ at Screening and at least once during the 12 months prior to Screening.~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs.~* Female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~* Positive test result at Screening for hepatitis B surface antigen (HBsAg).~* HCV genotype performed during screening indicating co-infection with more than one HCV genotype.~* Chronic HIV type 2 (HIV-2) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 for 12 weeks (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
- ABT-493/ABT-530 for 8 weeks (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® in the Treatment of Crow's Feet Lines in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Moderate to severe Crow's Feet Lines.~Exclusion Criteria:~* Current or previous treatment with botulinum toxin of any serotype for any condition within the last year~* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis~* Facial laser or light treatment, microdermabrasion or chemical peels within 3 months~* Radio frequency laser treatments, phototherapy, blepharoplasty, brow-lift or related procedure, permanent make-up, oral retinoid therapy or treatment with non-permanent soft tissue fillers within 1 year~* Any medium-depth or deep facial peels within 5 years~* Periorbital surgery, face-lift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- botulinum toxin type A (Type: EXPERIMENTAL): 24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
- placebo (Type: PLACEBO_COMPARATOR): Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete